Listed

Iradimed Corp: Form 10-Q for the period ended Sep 30, 2021

Filed with the SEC on Nov 5, 2021 and accepted by EDGAR at Nov 5, 2021, 07:00 ET.

Share

Management's discussion and analysis

As filed, 27,548 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion and analysis should be read in conjunction with our condensed financial statements and the related notes to those statements included in this Quarterly Report, the discussion of certain risks and uncertainties contained in Part II, Item 1A of this Quarterly Report, the discussion under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business” included in our Annual Report filed on Form 10-K for the fiscal year ended December 31, 2020 and the cautionary information regarding forward-looking statements at the beginning of this Quarterly Report.

Our Business

We develop, manufacture, market and distribute Magnetic Resonance Imaging (“MRI”) compatible medical devices and accessories and services relating to them.

We are a leader in the development of innovative MRI compatible medical devices. We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.

Each IV infusion pump system consists of an MRidium® MRI compatible IV infusion pump, non-magnetic mobile stand, proprietary disposable IV tubing sets and many of these systems contain additional optional upgrade accessories.

Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The IRADIMED 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the IRADIMED 3880 include: wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The IRADIMED 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.

We generate revenue from the sale of MRI compatible medical devices and accessories, extended warranty agreements, services related to maintaining our products and the sale of disposable products used with our devices. The principal customers for our MRI compatible products include hospitals and acute care facilities, both in the U.S. and internationally.

Selling cycles for our devices have varied widely and have historically ranged between three and six months in duration with more recent trends lengthening beyond this historical range due to the COVID-19 pandemic. We also enter into agreements with healthcare supply contracting companies, commonly referred to as Group Purchasing Organizations (“GPOs”), in the U.S., which facilitates our ability to sell and distribute our products to their member hospitals. Under these agreements, we are required to pay these GPOs a fee of three percent of the sales of our products to their member hospitals.

Financial Highlights

Beginning in the second quarter 2020, our business was significantly impacted by the COVID-19 pandemic, which negatively impacted our operations and financial results. Additionally, during the nine months ended September 30, 2020, we recognized $2.8 million of general and administrative expense related to the separation of our former CEO.

For the third quarter ended September 30, 2021, our revenue increased $3.2 million, or 41.7 percent, to $10.9 million, compared to $7.7 million for the third quarter last year. Income before the provision for income taxes was $3.1 million for the third quarter 2021, compared to $0.8 million for the third quarter last year. Net income was $2.6 million, or $0.20 per diluted share in the third quarter ended September 30, 2021, compared to $1.1 million, or $0.09 per share in the third quarter last year.

For the remainder of 2021, we expect higher revenue when compared to the same period in 2020 due to higher sales of our medical devices, related accessories, disposables, and services. We also expect higher operating expenses compared to the same period in 2020 primarily due to higher sales and marketing, and general and administrative expenses.

Effects of the COVID-19 Pandemic

The COVID-19 pandemic, and related governmental and societal responses thereto, continue to cause disruption in global supply and distribution channels and significantly change the way companies manage their business. From the beginning of this global health crisis, our priority has been the safety and well-being of our employees and continuing to supply our customers with access to our therapeutic and diagnostic device solutions.

We continue to monitor the developments associated with the COVID-19 pandemic and its effects on our employees, customers, supply chain and distribution channels. The ongoing impact of the pandemic depends on several factors including the severity and duration of the pandemic and the extent and severity of the impact on our customers, which is uncertain and unpredictable. Our future results of operations and cash flows may suffer adverse effects from disruptions in our supply chain and manufacturing operations, delays in payments on outstanding accounts receivable, uncertain demand for our products, and effects of any actions we may take to address financial and operational challenges our customers may face. Our future results may potentially be heavily determined by global vaccination rates, duration of the pandemic, its geographic spread, further business disruptions and the overall impact on the global economy. Other risks and uncertainties that we face include, but are not limited to:

  • disruptions in our supply chain that may limit our ability to procure materials necessary to manufacture our products or procuring materials at elevated costs resulting in diminished financial results;
  • postponement or cancellation of MRI medical procedures and their uncertain return which adversely impacts our business;
  • potential temporary or prolonged closure of our office and production facility;
  • the health of our employees and ability to meet staffing needs;
  • potential new or continued governmental actions that may limit employees’ ability to work;
  • civil unrest relating to government, corporate and societal responses to the pandemic;
  • volatility in economic conditions and the financial markets, and
  • other unanticipated effects that remain unknown.

We are actively managing our response to the COVID-19 pandemic and working with our customers, distributors, vendors, and suppliers and assessing the potential effects to our financial position, results of operations and cash flows. As of the date of the issuance of these financial statements, the extent to which COVID-19,or its variants, may materially impact our financial condition, liquidity, or results of operations in future periods remains uncertain.

Application of Critical Accounting Policies

We prepare our financial statements in conformity with GAAP. The preparation of these financial statements requires us to make estimates and use assumptions that affect the reported amounts of assets, liabilities and related disclosures at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

We believe that the following critical accounting policies require the use of significant estimates, assumptions, and judgments:

  • Revenue recognition;
  • Accounts receivable and allowance for doubtful accounts;
  • Inventory carried at the lower of cost or net realizable value;
  • Stock-based compensation; and
  • Income taxes.

These critical accounting policies are described in more detail in our Annual Report filed on Form 10-K, under Management’s Discussion and Analysis and Results of Operations. Except as disclosed in Note 1 to the unaudited condensed financial statements contained herein related to the adoption of recent accounting pronouncements, there have been no changes to these policies during the three and nine months ended September 30, 2021.

The use of different estimates, assumptions, and judgments could have a material effect on the reported amounts of assets, liabilities and related disclosures as of the date of the financial statements and revenue and expenses during the reporting period.

Results of Operations

The following table sets forth selected statements of operations data as a percentage of total revenue for the periods indicated. Our historical operating results are not necessarily indicative of the results for any future period.

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Percent of Revenue Three Months Ended September 30, 2021 ​ ​ ​ ​ ​ 2020 ​ ​ Percent of Revenue Nine Months Ended September 30, 2021 ​ ​ ​ ​ ​ 2020
Revenue 100.0% 100.0% 100.0% 100.0%
Cost of revenue 22.9 25.4 23.9 26.1
Gross profit 77.1 74.6 76.1 73.9
Operating expenses: ​ ​ ​ ​
General and administrative 20.6 28.5 24.2 43.4
Sales and marketing 23.7 29.6 24.8 30.6
Research and development 4.4 6.2 4.7 6.0
Total operating expenses 48.8 64.4 53.7 80.0
Income (loss) from operations 28.3 10.2 22.4 (6.1)
Other income, net 0.1 0.1 0.0 0.5
Income (loss) before provision for income taxes 28.4 10.3 22.5 (5.5)
Provision for income tax expense (benefit) 4.7 (3.6) 4.3 (8.7)
Net income 23.6% 14.0% 18.1% 3.2%

Three and Nine Months Ended September 30, 2021 and 2020

Revenue by Geographic Region

​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2021 ​ ​ ​ 2020 ​ ​ ​ ​ Nine Months Ended September 30, 2021 ​ ​ ​ 2020
United States ​ $8,676,488 ​ $6,465,184 ​ $23,992,474 ​ $17,430,206
International ​ 2,230,814 ​ 1,233,912 ​ 5,949,247 ​ 5,741,123
Total revenue ​ $10,907,302 ​ $7,699,096 ​ $29,941,721 ​ $23,171,329

Revenue by Type

​ ​ ​ ​ Devices: ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2021 ​ ​ ​ ​ ​ ​ 2020 ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2021 ​ ​ ​ ​ ​ ​ 2020 ​ ​
MRI Compatible IV Infusion Pump Systems ​ $3,369,068 ​ $2,153,699 ​ $9,329,182 ​ $6,693,692
MRI Compatible Patient Vital Signs Monitoring Systems ​ 3,779,442 ​ 2,282,943 ​ 9,760,991 ​ 6,829,932
Total Devices revenue ​ 7,148,510 ​ 4,436,642 ​ 19,090,173 ​ 13,523,624
Disposables, services and other ​ 3,285,656 ​ 2,802,039 ​ 9,412,091 ​ 8,269,487
Amortization of extended warranty agreements ​ 473,136 ​ 460,415 ​ 1,439,457 ​ 1,378,218
Total revenue ​ $10,907,302 ​ $7,699,096 ​ $29,941,721 ​ $23,171,329

For the three months ended September 30, 2021, revenue increased $3.2 million, or 41.7 percent, to $10.9 million from $7.7 million for the same period in 2020.

Revenue from sales in the U.S. increased $2.2 million, or 34.2 percent, to $8.7 million for the third quarter 2021, from $6.5 million for the third quarter 2020. Revenue from sales internationally increased $1.0 million, or 80.8 percent, to $2.2 million for the third quarter 2021, from $1.2 million for the third quarter 2020. Domestic sales accounted for 79.5 percent of revenue for the third quarter 2021, compared to 84.0 percent for the third quarter 2020.

Revenue from sales of devices increased $2.7 million, or 61.1 percent, to $7.1 million for the three months ended September 30, 2021, from $4.4 million for the same period in 2020.

The average selling price of our MRI compatible IV infusion pump system during the three months ended September 30, 2021 was approximately $33,000, compared to approximately $37,800 for the same period in 2020. The decrease in ASP is the result of higher international unit sales when compared to the same period in 2020.

The average selling price of our MRI compatible patient vital signs monitoring system during the three months ended September 30, 2021 was approximately $40,600, compared to approximately $43,000 for the same period in 2020. The decrease in ASP relates to higher international unit sales and when compared to the same period in 2020.

Revenue from sales of our disposables, service and other increased $0.5 million, or 17.3 percent, to $3.3 million for the three months ended September 30, 2021, from $2.8 million for the same period in 2020. Revenue from the amortization of extended warranty agreements was consistent at $0.5 million for the three months ended September 30, 2021 and 2020.

For the nine months ended September 30, 2021, revenue increased $6.7 million, or 29.2 percent, to $29.9 million from $23.2 million for the same period in 2020.

Revenue from sales in the U.S. increased $6.6 million, or 37.6 percent, to $24.0 million for the nine months ended September 30, 2021, from $17.4 million for the same period in 2020. Revenue from sales internationally increased $0.2 million, or 3.6 percent, to $5.9 million for the nine months ended September 30, 2021, from $5.7 million for the same period in 2020. Domestic sales accounted for 80.1 percent of revenue for the nine months ended September 30, 2021, compared to 75.2 percent for the same period in 2020.

Revenue from sales of devices increased $5.6 million, or 41.2 percent, to $19.1 million for the nine months ended September 30, 2021, from $13.5 million for the same period in 2020.

The average selling price of our MRI compatible IV infusion pump system during the nine months ended September 30, 2021 was approximately $34,800, compared to approximately $32,200 for the same period in 2020. The increase in ASP relates to higher domestic sales unit when compared to the same period in 2020.

The average selling price of our MRI compatible patient vital signs monitoring system during the nine months ended September 30, 2021 was approximately $39,700, compared to approximately $35,800 for the same period in 2020. The increase in ASP relates to higher domestic unit sales when compared to the same period in 2020.

Revenue from sales of our disposables, service and other increased $1.1 million, or 13.8 percent, to $9.4 million for the nine months ended September 30, 2021, from $8.3 million for the same period in 2020. Revenue from the amortization of extended warranty agreements was consistent at $1.4 million for the nine months ended September 30, 2021 and 2020.

Cost of Revenue and Gross Profit

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2021 ​ ​ ​ ​ 2020 ​ ​ ​ Nine Months Ended September 30, 2021 ​ ​ ​ ​ 2020
Revenue ​ $10,907,302 ​ $7,699,096 ​ $29,941,721 ​ $23,171,329 ​
Cost of revenue ​ 2,501,745 ​ 1,958,036 ​ 7,141,547 ​ 6,036,353 ​
Gross profit ​ $8,405,557 ​ $5,741,060 ​ $22,800,174 ​ $17,134,976 ​
Gross profit percentage ​ 77.1% 74.6% 76.1% 73.9%

For the three months ended September 30, 2021, cost of revenue increased $0.5 million, or 27.8 percent, to $2.5 million from $2.0 million for the same period last year. Gross profit increased $2.7 million, or 46.4 percent, to $8.4 million for the third quarter 2021 from $5.7 million for the same period in 2020. Gross profit margin was 77.1 percent for third quarter 2021, compared to 74.6 percent for the third quarter 2020. The increase in gross profit margin is primarily due to favorable overhead absorption from higher unit production, partially offset by an unfavorable geographic sales mix.

For the nine months ended September 30, 2021, cost of revenue increased $1.1 million, or 18.3 percent, to $7.1 million from $6.0 million for the same period last year. Gross profit increased $5.7 million, or 33.1 percent, to $22.8 million for the nine months ended September 30, 2021 from $17.1 million for the same period in 2020. Gross profit margin was 76.1 percent for nine months ended September 30, 2021, compared to 73.9 percent for the same period in 2020. The increase in gross profit margin is primarily due to favorable overhead absorption from higher unit production and a favorable geographic sales mix, partially offset by unfavorable inventory reserve adjustments.

Operating Expenses

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2021 ​ ​ ​ ​ 2020 ​ ​ ​ Nine Months Ended September 30, 2021 ​ ​ ​ ​ 2020
General and administrative ​ $2,252,274 ​ $2,196,935 ​ $7,247,262 ​ $10,062,089 ​
Percentage of revenue ​ 20.6% 28.5% 24.2% 43.4%
Sales and marketing ​ $2,585,702 ​ $2,282,491 ​ $7,434,603 ​ $7,090,192 ​
Percentage of revenue ​ 23.7% 29.6% 24.8% 30.6%
Research and development ​ $480,696 ​ $476,876 ​ $1,410,192 ​ $1,389,812 ​
Percentage of revenue ​ 4.4% 6.2% 4.7% 6.0%

General and Administrative

For the three months ended September 30, 2021, general and administrative expense increased $0.1 million, or 2.5 percent, to $2.3 million from $2.2 million for the same period last year. This increase is primarily due to higher payroll and benefits expenses, partially offset by lower stock compensation expense.

For the nine months ended September 30, 2021, general and administrative expense decreased $(2.9) million, or (28.0) percent, to $7.2 million from $10.1 million for the same period last year. This decrease is primarily due to stock and cash compensation expenses incurred during the nine months ended September 30, 2020 related to the separation of our former Chief Executive Officer, partially offset by higher regulatory affairs expenses.

Sales and Marketing

For the three months ended September 30, 2021, sales and marketing expense increased $0.3 million, 13.3 percent, to $2.6 million from $2.3 million for the same period last year. This increase is primarily due to higher sales commissions and sales activities expenses, partially offset by lower payroll and benefits expenses.

For the nine months ended September 30, 2021, sales and marketing expense increased $0.3 million, 4.9 percent, to $7.4 million from $7.1 million for the same period last year. This increase is primarily due to higher sales commissions and sales activities expenses, partially offset by lower payroll and benefits expenses.

Research and Development

For the three months ended September 30, 2021, research and development expense was consistent at $0.5 million. For the nine months ended September 30, 2021, research and development expense was consistent at $1.4 million. There were no significant changes in these accounts during the three and nine months ended September 30, 2021, compared to the same periods last year.

Other Income, Net

Other income, net consists of interest income, foreign currency gains and losses, and other miscellaneous income. For the three months ended September 30, 2021, we reported other income of approximately $7,000, compared to $9,000 for the three months ended September 30, 2020. There were no significant changes in these accounts during the three months ended September 30, 2021, compared to the same quarter last year.

For the nine months ended September 30, 2021, we reported other income of approximately $15,000, compared to $126,000 for the nine months ended September 30, 2020. This decrease is primarily due to lower interest income during the nine months ended September 30, 2021.

Income Taxes

For the three and nine months ended September 30, 2021, we recorded a provision for income tax expense of $517,767 and $1,289,988, respectively. Our effective tax rate was 16.7 percent and 19.2 percent, respectively, and differed from the U.S. Federal statutory rate primarily due to benefits from foreign derived intangible income, stock compensation and research and development tax credits, partially offset by U.S. state income tax expense.

For the three and nine months ended September 30, 2020, we recorded a provision for income tax benefit of $(280,536) and $(2,012,998), respectively. Our effective tax rate was (35.3) percent and 157.1 percent, respectively, and differed from the U.S. Federal statutory rate primarily due to discrete items related to tax benefits associated with stock-based compensation and a U.S. state tax benefit, partially offset by a limitation on the deductibility of certain executive compensation associated with the separation of our former Chief Executive Officer. Additionally, we recognized a benefit in our effective tax rate resulting from the Coronavirus Aid, Relief, and Economic Security Act, which allowed us to carryback net operating losses to years prior to the enactment of the Tax Cuts and Jobs Act.

As of September 30, 2021, and December 31, 2020, we had not identified or accrued for any uncertain tax positions. We are currently unaware of any uncertain tax positions that could result in significant payments, accruals or other material deviations in this estimate over the next 12 months. We believe that our tax positions comply in all material respects with applicable tax law. However, tax law is subject to interpretation, and interpretations by taxing authorities could be different from ours, which could result in the imposition of additional taxes and penalties.

We file tax returns in the United States Federal jurisdiction and many U.S. state jurisdictions. Our returns are not currently under examination by the Internal Revenue Service. The Company remains subject to income tax examinations for our United States Federal and certain U.S. state income taxes for 2017 and subsequent years and various other U.S. state income taxes for 2016 and subsequent years.

Liquidity and Capital Resources

Our principal sources of liquidity have historically been our cash and cash equivalents balances, our investments, cash flow from operations and access to the financial markets. Our principal uses of cash are operating expenses, working capital requirements and capital expenditures.

As of September 30, 2021, we had cash and investments of $59.3 million, stockholders’ equity of $67.9 million, and working capital of $65.3 million. As of December 31, 2020, we had cash and investments of $52.0 million, stockholders’ equity of $61.4 million, and working capital of $58.8 million.

We believe that our current cash, investments and any cash generated from operations will be sufficient to meet our ongoing operating requirements for at least the next 12 months. We do not anticipate requiring additional capital; however, if required or desirable, we may seek to obtain a credit facility, raise debt or issue additional equity in private or public markets.

​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2021 ​ ​ ​ 2020
Net cash provided by operating activities ​ $7,892,113 ​ $3,321,428
Net cash provided by (used in) investing activities ​ ​ 388,463 ​ ​ (53,564)
Net cash provided by financing activities ​ ​ 22,268 ​ ​ 799,974

Cash provided by operating activities increased $4.6 million, to $7.9 million for the nine months ended September 30, 2021, compared to $3.3 million for the same period in 2020. During the nine months ended September 30, 2021, cash provided by operations was positively impacted by net income and cash inflows from accounts receivable and deferred revenue, and negatively impacted by cash outflows from prepaid expenses, income tax payments and inventory purchases.

Cash provided by (used in) investing activities increased $0.5 million, to $0.4 million for the nine months ended September 30, 2021, compared to $(0.1) million for the same period in 2020. During the nine months ended September 30, 2021, cash provided by (used in) investing activities was positively impacted by cash inflows from maturities of securities, and negatively impacted by capital expenditures and capitalized intangible assets.

Cash provided by financing activities decreased $(0.8) million, to approximately $22,000 for the nine months ended September 30, 2021, compared to approximately $0.8 million for the same period in 2020. This decrease is primarily due to lower proceeds from the exercise of stock options, partially offset by lower cash outflows for the net share settlement of restricted stock units.

We market our products to end users in the U.S. and to distributors internationally. Sales to end users in the U.S. are generally made on open credit terms. Management maintains an allowance for potential credit losses.

Our manufacturing and headquarters facility has been leased from Susi, LLC, an entity controlled by our Chairman of the Board and Chief Executive Officer, Roger Susi. Pursuant to the terms of our lease, the monthly base rent is $34,133, adjusted annually for changes in the consumer price index.

Off-Balance Sheet Arrangements

As of September 30, 2021 and December 31, 2020, we did not have any off-balance sheet arrangements, as such term is defined under Item 303 of Regulation S-K, that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Contractual Obligations

There have been no material changes outside the ordinary course of business to our contractual obligations and commercial commitments since December 31, 2020.

Recent Accounting Pronouncements

See Note 1 to the unaudited condensed financial statements contained herein for a full description of recent accounting pronouncements including the respective expected dates of adoption and status of evaluation of expected effects on results of our operations and financial condition.

Market risk

As filed, 2,106 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Foreign Currency Exchange Risk

We have foreign currency risks related to our revenue and operating expenses denominated in currencies other than the U.S. Dollar, principally the Japanese yen (“Yen”). The volatility of the Yen depends on many factors that we cannot forecast with reliable accuracy. We have experienced and will continue to experience fluctuations in our net income because of transaction gains (losses) related to revaluing Yen denominated accounts payable balances. In the event our Yen denominated accounts payable or expenses increase, our operating results may be affected by fluctuations in the Yen exchange rate. If the U.S. Dollar uniformly increased or decreased in strength by 10 percent relative to the Yen, our net income would have correspondingly increased or decreased by an immaterial amount for the three and nine months ended September 30, 2021 and 2020.

Interest Rate Risk

When able, we invest excess cash in bank money-market funds, corporate debt securities or discrete short-term investments. The fair value of our cash equivalents and short-term investments is sensitive to changes in the general level of interest rates in the U.S., and the fair value of these investments will decline if market interest rates increase. As of September 30, 2021, we had $0.9 million in corporate bonds, all of which are maturing in less than 1 year. These corporate bonds have fixed interest rates and semi-annual interest payment dates. If market interest rates were to change by 100 basis points from levels at September 30, 2021, we expect the corresponding change in fair value of our investments would be immaterial. This is based on sensitivity analyses performed on our financial position as of September 30, 2021. Actual results may differ as our analysis of the effects of changes in interest rates does not account for, among other things, sales of securities prior to maturity and repurchase of replacement securities, the change in mix or quality of the investments in the portfolio, and changes in the relationship between short-term and long-term interest rates.

Controls and procedures

As filed, 1,830 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are designed to ensure that: (1) information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (2) such information is accumulated and communicated to management, including the principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.

Our management, including our Chief Executive Officer and Chief Financial and Operating Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2021. Our Chief Executive

Officer and Chief Financial and Operating Officer have concluded that our disclosure controls and procedures as of September 30, 2021 were effective.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 981 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We operate in a rapidly changing environment that involves a number of risks that could materially affect our business, financial condition or future results, some of which are beyond our control. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. In evaluating the Company and its business, you should carefully consider the information included in this Quarterly Report on Form 10-Q and the factors discussed under Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as well as in other documents we file with the SEC. There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-07-01 to 2021-09-30$10.9mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2021-01-01 to 2021-09-30$29.9mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2021-07-01 to 2021-09-30$2.5mus-gaap:CostOfRevenue
Cost of revenue9 months2021-01-01 to 2021-09-30$7.1mus-gaap:CostOfRevenue
Gross profit3 months2021-07-01 to 2021-09-30$8.4mus-gaap:GrossProfit
Gross profit9 months2021-01-01 to 2021-09-30$22.8mus-gaap:GrossProfit
Research and development3 months2021-07-01 to 2021-09-30$480.7kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2021-01-01 to 2021-09-30$1.4mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2021-07-01 to 2021-09-30$3.1mus-gaap:OperatingIncomeLoss
Operating income9 months2021-01-01 to 2021-09-30$6.7mus-gaap:OperatingIncomeLoss
Income tax3 months2021-07-01 to 2021-09-30$517.8kus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2021-01-01 to 2021-09-30$1.3mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-07-01 to 2021-09-30$2.6mus-gaap:NetIncomeLoss
Net income9 months2021-01-01 to 2021-09-30$5.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2021-07-01 to 2021-09-30$0.20us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2021-01-01 to 2021-09-30$0.43us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-07-01 to 2021-09-30$0.21us-gaap:EarningsPerShareBasic
Basic EPS9 months2021-01-01 to 2021-09-30$0.44us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-07-01 to 2021-09-3012,603,566 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2021-01-01 to 2021-09-3012,570,925 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2021-01-01 to 2021-09-30$7.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2021-01-01 to 2021-09-30$391.3kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-09-30$58.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-09-30$71.6mus-gaap:AssetsCurrent
Total assetsAt period end2021-09-30$78.4mus-gaap:Assets
Current liabilitiesAt period end2021-09-30$6.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-09-30$10.5mus-gaap:Liabilities
Shareholders' equityAt period end2021-09-30$67.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001104659-21-134722. Last ingested by Listed: Nov 6, 2026, 03:39 ET. Listed shows no prices and gives no investment advice.